Overview

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

Status:
RECRUITING

Trial end date:
2029-04-15

Target enrollment:

Participant gender:

Summary

This is a pivotal phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 2 to \<12 years) with homozygous familial hypercholesterolemia (HoFH) and elevated low density lipoprotein cholesterol (LDLC).

Phase:

PHASE3

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

ALN-PCS
Saline Solution